LY9 and neoplasm: To determine a possible link between SLAMF3 expression, sorafenib resistance and tumor aggressive phenotype, we analyzed the expression of SLAMF3 in three additional HCC cell lines: PLC/PRF/5 as epithelial origin cells such as Huh-7, SNU449 and SNU387, which are mesenchymal cells.